GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder
Standard
GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder. / Plage, Henning; Samtleben, Henrik; Hofbauer, Sebastian; Kornienko, Kira; Weinberger, Sarah; Bruch, Paul Giacomo; Elezkurtaj, Sefer; Roßner, Florian; Schallenberg, Simon; Kluth, Martina; Lennartz, Maximilian; Blessin, Niclas C; Marx, Andreas H; Fisch, Margit; Rink, Michael; Slojewski, Marcin; Kaczmarek, Krystian; Ecke, Thorsten; Hallmann, Steffen; Koch, Stefan; Adamini, Nico; Minner, Sarah; Simon, Ronald; Sauter, Guido; Klatte, Tobias; Schlomm, Thorsten; Horst, David; Zecha, Henrik.
In: HUM PATHOL, Vol. 130, 12.2022, p. 10-17.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder
AU - Plage, Henning
AU - Samtleben, Henrik
AU - Hofbauer, Sebastian
AU - Kornienko, Kira
AU - Weinberger, Sarah
AU - Bruch, Paul Giacomo
AU - Elezkurtaj, Sefer
AU - Roßner, Florian
AU - Schallenberg, Simon
AU - Kluth, Martina
AU - Lennartz, Maximilian
AU - Blessin, Niclas C
AU - Marx, Andreas H
AU - Fisch, Margit
AU - Rink, Michael
AU - Slojewski, Marcin
AU - Kaczmarek, Krystian
AU - Ecke, Thorsten
AU - Hallmann, Steffen
AU - Koch, Stefan
AU - Adamini, Nico
AU - Minner, Sarah
AU - Simon, Ronald
AU - Sauter, Guido
AU - Klatte, Tobias
AU - Schlomm, Thorsten
AU - Horst, David
AU - Zecha, Henrik
N1 - Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2022/12
Y1 - 2022/12
N2 - The transcription factor GATA binding protein 3 (GATA3) is commonly used in surgical pathology as a diagnostic marker to distinguish urothelial carcinomas from other cancer entities. However, the clinical relevance of GATA3 expression in urothelial bladder cancer is not completely clarified. In this study, we investigated GATA3 immunostaining on 2710 urothelial bladder carcinomas on a tissue microarray platform by using two different antibodies to better understand its impact in relation to pathological parameters of disease progression and patient outcome. Nuclear GATA3 immunostaining was regularly seen in normal urothelium and found in 74%/82% of interpretable urothelial neoplasms depending on the antibody used. Within pTa tumors, the rate of GATA3 positive tumors decreased with advancing grade. GATA3 positivity was seen in 98.6%/99.8% of pTaG2 low-grade, 98.6%/100% of pTaG2 high-grade, and 94.9%/99.2% of pTaG3 high-grade tumors (P = .0002). As compared to pTa tumors, GATA3 positivity was markedly less common in muscle-invasive urothelial carcinoma (59.9%/71.6%; P < .0001). Within pT2-4 cancers, high-level GATA3 immunostaining was associated with the presence of lymph node metastasis (P = .0034), and blood vessel (P = .0290) or lymphatic invasion (P = .0005) but unrelated to pT stage. GATA3 immunostaining results for both antibodies were not associated with overall survival in 586 patients treated by cystectomy for pT2-4 urothelial carcinoma. The results of our study identify GATA3 expression as a frequent event in noninvasive urothelial carcinomas with favorable tumor features. Loss of GATA3 immunostaining is linked with muscle-invasive disease but is largely unrelated to pathological parameters and patient prognosis.
AB - The transcription factor GATA binding protein 3 (GATA3) is commonly used in surgical pathology as a diagnostic marker to distinguish urothelial carcinomas from other cancer entities. However, the clinical relevance of GATA3 expression in urothelial bladder cancer is not completely clarified. In this study, we investigated GATA3 immunostaining on 2710 urothelial bladder carcinomas on a tissue microarray platform by using two different antibodies to better understand its impact in relation to pathological parameters of disease progression and patient outcome. Nuclear GATA3 immunostaining was regularly seen in normal urothelium and found in 74%/82% of interpretable urothelial neoplasms depending on the antibody used. Within pTa tumors, the rate of GATA3 positive tumors decreased with advancing grade. GATA3 positivity was seen in 98.6%/99.8% of pTaG2 low-grade, 98.6%/100% of pTaG2 high-grade, and 94.9%/99.2% of pTaG3 high-grade tumors (P = .0002). As compared to pTa tumors, GATA3 positivity was markedly less common in muscle-invasive urothelial carcinoma (59.9%/71.6%; P < .0001). Within pT2-4 cancers, high-level GATA3 immunostaining was associated with the presence of lymph node metastasis (P = .0034), and blood vessel (P = .0290) or lymphatic invasion (P = .0005) but unrelated to pT stage. GATA3 immunostaining results for both antibodies were not associated with overall survival in 586 patients treated by cystectomy for pT2-4 urothelial carcinoma. The results of our study identify GATA3 expression as a frequent event in noninvasive urothelial carcinomas with favorable tumor features. Loss of GATA3 immunostaining is linked with muscle-invasive disease but is largely unrelated to pathological parameters and patient prognosis.
KW - Humans
KW - Carcinoma, Transitional Cell/pathology
KW - Urinary Bladder Neoplasms/metabolism
KW - Urinary Bladder/pathology
KW - Immunohistochemistry
KW - Biomarkers, Tumor/metabolism
KW - GATA3 Transcription Factor/metabolism
KW - Urothelium/pathology
KW - Prognosis
KW - Muscles/metabolism
U2 - 10.1016/j.humpath.2022.09.004
DO - 10.1016/j.humpath.2022.09.004
M3 - SCORING: Journal article
C2 - 36152841
VL - 130
SP - 10
EP - 17
JO - HUM PATHOL
JF - HUM PATHOL
SN - 0046-8177
ER -
